US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Acrivon Therapeutics, Inc.

2.22

+0.00500.23%

Volume:131.32K

Turnover:282.36K

Market Cap:94.81M

PE:-1.18

High:2.23

Open:2.19

Low:2.06

Close:2.21

52wk High:3.56

52wk Low:1.27

Shares:42.80M

Float Shares:25.69M

Volume Ratio:0.36

T/O Rate:0.51%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.8800

EPS(LYR):-2.0151

ROE:-64.63%

ROA:-38.02%

PB:1.09

PE(LYR):-1.10

Loading ...

Overview Company News Filings

Acrivon Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Acrivon Therapeutics, Inc Q2 Income from Operations USD -18.668 Million

Acrivon Therapeutics, Inc Q2 Basic EPS USD -0.43

THOMSON REUTERS

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Acrivon Therapeutics, Inc. Expected to Post a Loss of 50 Cents a Share - Earnings Preview

Acrivon Advances ACR-2316 into Randomized Dose Expansion in Phase 1/2 Trial

Acrivon Advances Acr-2316, a Potential First-in-Class Wee1/Pkmyt1 Inhibitor, into Randomized Dose Expansion in Its Ongoing Phase 1/2 Study

THOMSON REUTERS

Acrivon Therapeutics Announces Availability of New Press Release

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Simply Wall St.

Acrivon Therapeutics shareholders approve amended 2022 equity incentive plan

Acrivon CEO joins TD Cowen Oncology Innovation Summit virtual fireside chat

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock

Simply Wall St.

Acrivon grants employee stock options for 111,150 shares under inducement plan

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer

Acrivon Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Acrivon Therapeutics Q1 net loss narrows

Acrivon net loss narrows to $19 million in Q1 FY26

Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts

THOMSON REUTERS

Acrivon Therapeutics, Inc Q1 Income From Operations USD -19.902 Million

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/ACRV/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ACRV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","market":"US","secType":"STK","nameCN":"Acrivon Therapeutics, Inc.","latestPrice":2.215,"timestamp":1787590630469,"preClose":2.21,"halted":0,"volume":131321,"delay":0,"changeRate":0.0022624434389139788,"floatShares":25689899,"shares":42801400,"eps":-1.88,"marketStatus":"Trading","change":0.005,"latestTime":"08-24 12:58:20 EDT","open":2.19,"high":2.225,"low":2.06,"amount":282364.9959332,"amplitude":0.074661,"askPrice":2.22,"askSize":184,"bidPrice":2.21,"bidSize":238,"shortable":3,"etf":0,"ttmEps":-1.88,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1668488400000,"exchange":"NASDAQ","adjPreClose":2.21,"preHourTrading":{"tag":"盘前","latestPrice":2.204,"preClose":2.21,"latestTime":"08:27 EDT","volume":3328,"amount":7260.4190464,"timestamp":1787574450783,"change":-0.006,"changeRate":-0.002715,"amplitude":0.0181},"postHourTrading":{"tag":"盘后","latestPrice":2.2,"preClose":2.21,"latestTime":"19:55 EDT","volume":731,"amount":1604.0325,"timestamp":1787356537762,"change":-0.01,"changeRate":-0.004525,"amplitude":0.01362},"volumeRatio":0.357226},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACRV\",,,,,undefined,":{"symbol":"ACRV","floatShares":25689899,"roa":"-38.02%","roe":"-64.63%","lyrEps":-2.015099,"volumeRatio":0.357226,"shares":42801400,"dividePrice":0,"high":2.225,"amplitude":0.074661,"preClose":2.21,"low":2.06,"week52Low":1.27,"pbRate":"1.09","week52High":3.56,"institutionHeld":0,"latestPrice":2.215,"committee":0.127962,"eps":-1.88,"divideRate":0,"volume":131321,"delay":0,"ttmEps":-1.88,"open":2.19,"prevYearClose":2.41,"prevWeekClose":2.21,"prevMonthClose":1.5,"prevQuarterClose":1.78,"fiveDayClose":2.05,"twentyDayClose":1.56,"sixtyDayClose":1.63},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACRV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"ACRV","fiscalQuarterEnding":"2026/06","expectedEps":-0.49,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.43},{"market":"US","date":"2026-05-13","symbol":"ACRV","fiscalQuarterEnding":"2026/03","expectedEps":-0.49,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2026-03-19","symbol":"ACRV","fiscalQuarterEnding":"2025/12","expectedEps":-0.49,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-11-13","symbol":"ACRV","fiscalQuarterEnding":"2025/09","expectedEps":-0.57,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1763010000000,"reportTimeType":"post","actualEps":-0.47},{"market":"US","date":"2025-08-13","symbol":"ACRV","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"post","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACRV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACRV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1747454400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ACRV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ACRV","date":"2026-08-21","current":-1.167553,"percent":0.622581,"low":-18.228389,"twenty":-6.10495,"median":-2.265134,"eighty":-0.728225,"high":-0.393112,"avg":-3.67247,"sd":3.919896,"marketCap":94277396},"quantilePoints":[{"date":"2022-11-11","current":-11.86111,"twenty":-16.13111,"median":-16.13111,"eighty":-13.56911,"marketCap":235122787},{"date":"2022-11-18","current":-16.605358,"twenty":-17.148347,"median":-16.336664,"eighty":-13.56911,"marketCap":329168006},{"date":"2022-11-25","current":-13.1538,"twenty":-16.59273,"median":-14.65824,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-02","current":-13.311646,"twenty":-16.459997,"median":-13.18537,"eighty":-13.1538,"marketCap":263876760},{"date":"2022-12-09","current":-13.1538,"twenty":-16.13111,"median":-13.18537,"eighty":-13.1538,"marketCap":260747787},{"date":"2022-12-16","current":-9.42062,"twenty":-15.609309,"median":-13.164324,"eighty":-13.1538,"marketCap":250409495},{"date":"2022-12-23","current":-9.15348,"twenty":-13.492642,"median":-13.1538,"eighty":-9.908718,"marketCap":243308642},{"date":"2022-12-30","current":-9.051338,"twenty":-13.374784,"median":-13.1538,"eighty":-9.15348,"marketCap":240593610},{"date":"2023-01-06","current":-9.114194,"twenty":-13.324274,"median":-13.1538,"eighty":-9.10948,"marketCap":242264399},{"date":"2023-01-13","current":-9.758474,"twenty":-13.286391,"median":-13.1538,"eighty":-9.096909,"marketCap":259389986},{"date":"2023-01-20","current":-11.102032,"twenty":-13.261136,"median":-11.86111,"eighty":-9.107908,"marketCap":295103100},{"date":"2023-01-27","current":-11.416314,"twenty":-13.210625,"median":-11.432028,"eighty":-9.118908,"marketCap":303457044},{"date":"2023-02-03","current":-14.967707,"twenty":-13.261136,"median":-11.549884,"eighty":-9.140908,"marketCap":397856621},{"date":"2023-02-10","current":-17.254113,"twenty":-13.707494,"median":-12.294777,"eighty":-9.280764,"marketCap":458631569},{"date":"2023-02-17","current":-16.963401,"twenty":-16.209458,"median":-13.1538,"eighty":-9.39862,"marketCap":450904170},{"date":"2023-02-24","current":-12.044879,"twenty":-16.13111,"median":-12.885585,"eighty":-9.423763,"marketCap":320164934},{"date":"2023-03-03","current":-16.499835,"twenty":-16.177918,"median":-13.1538,"eighty":-9.434763,"marketCap":438582102},{"date":"2023-03-10","current":-15.745556,"twenty":-16.430693,"median":-13.1538,"eighty":-9.447334,"marketCap":418532634},{"date":"2023-03-17","current":-15.714128,"twenty":-16.525265,"median":-13.1538,"eighty":-9.527476,"marketCap":417697240},{"date":"2023-03-24","current":-10.229897,"twenty":-16.430693,"median":-13.1538,"eighty":-9.461476,"marketCap":271920903},{"date":"2023-03-31","current":-8.928026,"twenty":-16.282979,"median":-13.1538,"eighty":-9.434763,"marketCap":278259784},{"date":"2023-04-06","current":-7.274688,"twenty":-16.215409,"median":-13.019693,"eighty":-9.37662,"marketCap":226730194},{"date":"2023-04-14","current":-6.723819,"twenty":-16.19352,"median":-12.044879,"eighty":-9.115765,"marketCap":209561261},{"date":"2023-04-21","current":-8.060143,"twenty":-16.13111,"median":-11.86111,"eighty":-9.056052,"marketCap":251210465},{"date":"2023-04-28","current":-8.650938,"twenty":-16.126284,"median":-11.549884,"eighty":-9.035624,"marketCap":269623798},{"date":"2023-05-05","current":-7.956584,"twenty":-16.088124,"median":-11.377028,"eighty":-8.91982,"marketCap":247982856},{"date":"2023-05-12","current":-8.118522,"twenty":-16.003268,"median":-11.21203,"eighty":-8.835959,"marketCap":297974095},{"date":"2023-05-19","current":-7.88554,"twenty":-15.962411,"median":-10.807392,"eighty":-8.673871,"marketCap":289422962},{"date":"2023-05-26","current":-7.467367,"twenty":-15.908983,"median":-10.229897,"eighty":-8.438641,"marketCap":274074775},{"date":"2023-06-02","current":-7.419576,"twenty":-15.745556,"median":-9.829187,"eighty":-8.257075,"marketCap":272320696},{"date":"2023-06-09","current":-7.353863,"twenty":-15.714128,"median":-9.671273,"eighty":-8.064756,"marketCap":269908838},{"date":"2023-06-16","current":-7.138803,"twenty":-14.967707,"median":-9.475619,"eighty":-7.88554,"marketCap":262015484},{"date":"2023-06-23","current":-7.694375,"twenty":-14.936279,"median":-9.444191,"eighty":-7.691985,"marketCap":282406648},{"date":"2023-06-30","current":-7.957226,"twenty":-14.607853,"median":-9.4246,"eighty":-7.737387,"marketCap":292054080},{"date":"2023-07-07","current":-6.962573,"twenty":-14.230714,"median":-9.36562,"eighty":-7.687206,"marketCap":255547320},{"date":"2023-07-14","current":-7.312046,"twenty":-13.800187,"median":-9.122051,"eighty":-7.479315,"marketCap":268374019},{"date":"2023-07-21","current":-7.795931,"twenty":-13.463178,"median":-9.09848,"eighty":-7.467367,"marketCap":286134065},{"date":"2023-07-28","current":-7.335941,"twenty":-13.349529,"median":-9.063123,"eighty":-7.467367,"marketCap":269251058},{"date":"2023-08-04","current":-7.049195,"twenty":-13.305332,"median":-9.04741,"eighty":-7.451835,"marketCap":258726587},{"date":"2023-08-11","current":-6.929717,"twenty":-13.273763,"median":-9.035624,"eighty":-7.414797,"marketCap":254341391},{"date":"2023-08-18","current":-5.439761,"twenty":-13.23588,"median":-8.933664,"eighty":-7.374175,"marketCap":243684992},{"date":"2023-08-25","current":-5.824092,"twenty":-13.18537,"median":-8.917768,"eighty":-7.335941,"marketCap":260901867},{"date":"2023-09-01","current":-5.774819,"twenty":-13.181161,"median":-8.846512,"eighty":-7.295319,"marketCap":258694575},{"date":"2023-09-08","current":-5.764965,"twenty":-13.164324,"median":-8.810263,"eighty":-7.252307,"marketCap":258253117},{"date":"2023-09-15","current":-5.415125,"twenty":-13.164324,"median":-8.657972,"eighty":-7.138803,"marketCap":242581346},{"date":"2023-09-22","current":-4.666172,"twenty":-13.15801,"median":-8.650938,"eighty":-7.070701,"marketCap":209030514},{"date":"2023-09-28","current":-4.848483,"twenty":-13.1538,"median":-8.470778,"eighty":-7.024104,"marketCap":217197493},{"date":"2023-10-06","current":-3.606798,"twenty":-13.1538,"median":-8.337045,"eighty":-6.962573,"marketCap":161573745},{"date":"2023-10-13","current":-3.074648,"twenty":-13.1538,"median":-8.233741,"eighty":-6.723819,"marketCap":137734995},{"date":"2023-10-20","current":-2.670607,"twenty":-13.1538,"median":-8.118522,"eighty":-6.217422,"marketCap":119635204},{"date":"2023-10-27","current":-2.498151,"twenty":-13.1538,"median":-8.106574,"eighty":-6.135872,"marketCap":111909684},{"date":"2023-11-03","current":-2.650898,"twenty":-13.1538,"median":-8.060143,"eighty":-5.913769,"marketCap":118752288},{"date":"2023-11-10","current":-2.023663,"twenty":-13.1538,"median":-7.990082,"eighty":-5.83986,"marketCap":101314684},{"date":"2023-11-17","current":-1.968296,"twenty":-13.1538,"median":-7.956584,"eighty":-5.774819,"marketCap":98542723},{"date":"2023-11-24","current":-1.70231,"twenty":-13.1538,"median":-7.867618,"eighty":-5.710764,"marketCap":85226138},{"date":"2023-12-01","current":-1.795405,"twenty":-12.885585,"median":-7.837749,"eighty":-5.538308,"marketCap":89886943},{"date":"2023-12-08","current":-2.38944,"twenty":-12.728444,"median":-7.795931,"eighty":-5.434834,"marketCap":119627314},{"date":"2023-12-15","current":-2.220982,"twenty":-12.181592,"median":-7.694375,"eighty":-5.139195,"marketCap":111193478},{"date":"2023-12-22","current":-2.158919,"twenty":-11.988308,"median":-7.676453,"eighty":-4.765704,"marketCap":108086275},{"date":"2023-12-29","current":-2.207683,"twenty":-11.903452,"median":-7.658532,"eighty":-4.607044,"marketCap":110527648},{"date":"2024-01-05","current":-2.061391,"twenty":-11.878047,"median":-7.57191,"eighty":-4.424734,"marketCap":103203527},{"date":"2024-01-12","current":-2.136753,"twenty":-11.86111,"median":-7.467367,"eighty":-3.380635,"marketCap":106976559},{"date":"2024-01-19","current":-1.928398,"twenty":-11.771191,"median":-7.467367,"eighty":-3.021433,"marketCap":96545235},{"date":"2024-01-26","current":-1.795405,"twenty":-11.601741,"median":-7.461393,"eighty":-2.812514,"marketCap":89886943},{"date":"2024-02-02","current":-1.711176,"twenty":-11.509027,"median":-7.449445,"eighty":-2.678491,"marketCap":85670025},{"date":"2024-02-09","current":-1.569317,"twenty":-11.435171,"median":-7.416589,"eighty":-2.525448,"marketCap":78567846},{"date":"2024-02-16","current":-1.773239,"twenty":-11.384886,"median":-7.389706,"eighty":-2.417812,"marketCap":88777228},{"date":"2024-02-23","current":-1.693444,"twenty":-11.315743,"median":-7.371785,"eighty":-2.305211,"marketCap":84782252},{"date":"2024-03-01","current":-2.154486,"twenty":-11.224602,"median":-7.341915,"eighty":-2.222755,"marketCap":107864332},{"date":"2024-03-08","current":-2.274179,"twenty":-11.19003,"median":-7.329968,"eighty":-2.220982,"marketCap":113856794},{"date":"2024-03-15","current":-2.247581,"twenty":-11.059604,"median":-7.297111,"eighty":-2.213003,"marketCap":112525136},{"date":"2024-03-22","current":-2.806151,"twenty":-10.856891,"median":-7.272415,"eighty":-2.217436,"marketCap":140489963},{"date":"2024-03-28","current":-2.376071,"twenty":-10.724892,"median":-7.222437,"eighty":-2.220982,"marketCap":143486194},{"date":"2024-04-05","current":-2.507803,"twenty":-10.284897,"median":-7.147764,"eighty":-2.220982,"marketCap":151441202},{"date":"2024-04-12","current":-3.482435,"twenty":-10.229897,"median":-7.085038,"eighty":-2.220982,"marketCap":210297274},{"date":"2024-04-19","current":-5.388706,"twenty":-10.049185,"median":-7.03426,"eighty":-2.229848,"marketCap":325413151},{"date":"2024-04-26","current":-4.330392,"twenty":-9.829187,"median":-6.98405,"eighty":-2.238715,"marketCap":261503737},{"date":"2024-05-03","current":-4.325468,"twenty":-9.758474,"median":-6.941664,"eighty":-2.247581,"marketCap":261206357},{"date":"2024-05-10","current":-4.161857,"twenty":-9.701929,"median":-6.723819,"eighty":-2.252014,"marketCap":251326211},{"date":"2024-05-17","current":-4.122189,"twenty":-9.640618,"median":-6.484687,"eighty":-2.274179,"marketCap":264306537},{"date":"2024-05-24","current":-3.905485,"twenty":-9.530619,"median":-6.182256,"eighty":-2.300778,"marketCap":250411918},{"date":"2024-05-31","current":-3.717675,"twenty":-9.486619,"median":-5.962057,"eighty":-2.304324,"marketCap":238369915},{"date":"2024-06-07","current":-3.49134,"twenty":-9.456762,"median":-5.903338,"eighty":-2.319397,"marketCap":223857757},{"date":"2024-06-14","current":-3.49134,"twenty":-9.445762,"median":-5.863511,"eighty":-2.33713,"marketCap":223857757},{"date":"2024-06-21","current":-3.183139,"twenty":-9.434763,"median":-5.824092,"eighty":-2.361913,"marketCap":204096520},{"date":"2024-06-28","current":-2.793072,"twenty":-9.426151,"median":-5.774819,"eighty":-2.384092,"marketCap":179086205},{"date":"2024-07-05","current":-3.404659,"twenty":-9.423008,"median":-5.767428,"eighty":-2.38944,"marketCap":218299909},{"date":"2024-07-12","current":-3.587653,"twenty":-9.39862,"median":-5.666418,"eighty":-2.403626,"marketCap":230033143},{"date":"2024-07-19","current":-3.529865,"twenty":-9.280764,"median":-5.543235,"eighty":-2.426576,"marketCap":226327911},{"date":"2024-07-26","current":-4.266659,"twenty":-9.140908,"median":-5.474253,"eighty":-2.441598,"marketCap":273569617},{"date":"2024-08-02","current":-3.63581,"twenty":-9.122051,"median":-5.42498,"eighty":-2.474845,"marketCap":233120836},{"date":"2024-08-09","current":-3.703229,"twenty":-9.118908,"median":-5.388706,"eighty":-2.497195,"marketCap":237443607},{"date":"2024-08-16","current":-3.411328,"twenty":-9.107908,"median":-5.155584,"eighty":-2.500122,"marketCap":235388438},{"date":"2024-08-23","current":-4.201319,"twenty":-9.095337,"median":-5.020597,"eighty":-2.503539,"marketCap":289899445},{"date":"2024-08-30","current":-4.259671,"twenty":-9.084337,"median":-4.902952,"eighty":-2.504417,"marketCap":293925826},{"date":"2024-09-06","current":-3.62678,"twenty":-9.070195,"median":-4.859549,"eighty":-2.505321,"marketCap":250255077},{"date":"2024-09-13","current":-3.999333,"twenty":-9.051338,"median":-4.841316,"eighty":-2.507803,"marketCap":275961972},{"date":"2024-09-20","current":-3.352976,"twenty":-9.049767,"median":-4.688345,"eighty":-2.511616,"marketCap":231362057},{"date":"2024-09-27","current":-3.21383,"twenty":-9.04191,"median":-4.607044,"eighty":-2.532949,"marketCap":221760687},{"date":"2024-10-04","current":-3.146501,"twenty":-9.035624,"median":-4.498696,"eighty":-2.562206,"marketCap":217114862},{"date":"2024-10-11","current":-3.272182,"twenty":-9.016796,"median":-4.434588,"eighty":-2.595712,"marketCap":225787068},{"date":"2024-10-18","current":-3.703086,"twenty":-8.941048,"median":-4.32793,"eighty":-2.65484,"marketCap":255520344},{"date":"2024-10-25","current":-3.572917,"twenty":-8.937048,"median":-4.281106,"eighty":-2.672533,"marketCap":246538417},{"date":"2024-11-01","current":-3.59536,"twenty":-8.928026,"median":-4.264137,"eighty":-2.682254,"marketCap":248087025},{"date":"2024-11-08","current":-3.846721,"twenty":-8.925974,"median":-4.246205,"eighty":-2.692288,"marketCap":265431436},{"date":"2024-11-15","current":-2.815239,"twenty":-8.917768,"median":-4.204595,"eighty":-2.703682,"marketCap":216708620},{"date":"2024-11-22","current":-2.649398,"twenty":-8.907034,"median":-4.16553,"eighty":-2.65484,"marketCap":203942738},{"date":"2024-11-29","current":-3.066021,"twenty":-8.864099,"median":-4.160922,"eighty":-2.670607,"marketCap":236013123},{"date":"2024-12-06","current":-2.596815,"twenty":-8.828924,"median":-4.126009,"eighty":-2.650898,"marketCap":199895020},{"date":"2024-12-13","current":-2.855687,"twenty":-8.814854,"median":-4.120525,"eighty":-2.670607,"marketCap":219822249},{"date":"2024-12-20","current":-2.714117,"twenty":-8.805671,"median":-4.068333,"eighty":-2.680238,"marketCap":208924546},{"date":"2024-12-27","current":-2.394571,"twenty":-8.751109,"median":-4.0331,"eighty":-2.645353,"marketCap":184326872},{"date":"2025-01-03","current":-2.677713,"twenty":-8.689771,"median":-4.012605,"eighty":-2.604905,"marketCap":206122279},{"date":"2025-01-10","current":-2.212551,"twenty":-8.655158,"median":-3.960865,"eighty":-2.587876,"marketCap":170315539},{"date":"2025-01-17","current":-2.337942,"twenty":-8.650938,"median":-3.900584,"eighty":-2.551877,"marketCap":179967790},{"date":"2025-01-24","current":-2.204461,"twenty":-8.625618,"median":-3.852513,"eighty":-2.521343,"marketCap":169692813},{"date":"2025-01-31","current":-2.455244,"twenty":-8.502914,"median":-3.835171,"eighty":-2.504323,"marketCap":188997316},{"date":"2025-02-07","current":-2.43502,"twenty":-8.401182,"median":-3.809173,"eighty":-2.50322,"marketCap":187440501},{"date":"2025-02-14","current":-2.192327,"twenty":-8.329184,"median":-3.763471,"eighty":-2.461772,"marketCap":168758724},{"date":"2025-02-21","current":-2.240865,"twenty":-8.297738,"median":-3.75246,"eighty":-2.43502,"marketCap":172495079},{"date":"2025-02-28","current":-2.147833,"twenty":-8.257075,"median":-3.717675,"eighty":-2.390526,"marketCap":165333731},{"date":"2025-03-07","current":-2.240865,"twenty":-8.210407,"median":-3.714869,"eighty":-2.366257,"marketCap":172495079},{"date":"2025-03-14","current":-2.200416,"twenty":-8.154365,"median":-3.703229,"eighty":-2.322944,"marketCap":169381450},{"date":"2025-03-21","current":-2.168057,"twenty":-8.118522,"median":-3.698597,"eighty":-2.300778,"marketCap":166890546},{"date":"2025-03-28","current":-0.871783,"twenty":-8.106574,"median":-3.680643,"eighty":-2.269179,"marketCap":70227315},{"date":"2025-04-04","current":-0.587675,"twenty":-8.064756,"median":-3.655072,"eighty":-2.252014,"marketCap":47340734},{"date":"2025-04-11","current":-0.630486,"twenty":-8.060143,"median":-3.640625,"eighty":-2.24491,"marketCap":50789397},{"date":"2025-04-17","current":-0.704431,"twenty":-8.039938,"median":-3.63581,"eighty":-2.240865,"marketCap":56746178},{"date":"2025-04-25","current":-0.638341,"twenty":-8.020549,"median":-3.631295,"eighty":-2.235426,"marketCap":51422173},{"date":"2025-05-02","current":-0.548817,"twenty":-7.973953,"median":-3.617803,"eighty":-2.223945,"marketCap":44210527},{"date":"2025-05-09","current":-0.451509,"twenty":-7.958421,"median":-3.612522,"eighty":-2.214841,"marketCap":36371781},{"date":"2025-05-16","current":-0.430551,"twenty":-7.956712,"median":-3.606138,"eighty":-2.211394,"marketCap":36058665},{"date":"2025-05-23","current":-0.430551,"twenty":-7.899749,"median":-3.596322,"eighty":-2.204461,"marketCap":36058665},{"date":"2025-05-30","current":-0.411832,"twenty":-7.874787,"median":-3.589262,"eighty":-2.194384,"marketCap":34490897},{"date":"2025-06-06","current":-0.46799,"twenty":-7.860449,"median":-3.572307,"eighty":-2.185046,"marketCap":39194201},{"date":"2025-06-13","current":-0.475478,"twenty":-7.85567,"median":-3.556351,"eighty":-2.168057,"marketCap":39821308},{"date":"2025-06-20","current":-0.464247,"twenty":-7.841333,"median":-3.540333,"eighty":-2.161322,"marketCap":38880647},{"date":"2025-06-27","current":-0.490454,"twenty":-7.815048,"median":-3.529865,"eighty":-2.150494,"marketCap":41075522},{"date":"2025-07-03","current":-0.482966,"twenty":-7.805489,"median":-3.520234,"eighty":-2.141361,"marketCap":40448415},{"date":"2025-07-11","current":-0.50543,"twenty":-7.789957,"median":-3.49134,"eighty":-2.109268,"marketCap":42329737},{"date":"2025-07-18","current":-0.494198,"twenty":-7.751725,"median":-3.478657,"eighty":-2.07907,"marketCap":41389076},{"date":"2025-07-25","current":-0.520405,"twenty":-7.691985,"median":-3.452815,"eighty":-2.037985,"marketCap":43583951},{"date":"2025-08-01","current":-0.479222,"twenty":-7.680037,"median":-3.411328,"eighty":-2.021493,"marketCap":40134862},{"date":"2025-08-08","current":-0.475478,"twenty":-7.66809,"median":-3.410401,"eighty":-1.970956,"marketCap":39821308},{"date":"2025-08-15","current":-0.508659,"twenty":-7.656142,"median":-3.404659,"eighty":-1.930615,"marketCap":43723346},{"date":"2025-08-22","current":-0.483043,"twenty":-7.616715,"median":-3.37891,"eighty":-1.884954,"marketCap":41521451},{"date":"2025-08-29","current":-0.486703,"twenty":-7.496042,"median":-3.352976,"eighty":-1.788312,"marketCap":41836007},{"date":"2025-09-05","current":-0.475725,"twenty":-7.491263,"median":-3.313162,"eighty":-1.768806,"marketCap":40892338},{"date":"2025-09-12","current":-0.56721,"twenty":-7.467367,"median":-3.258716,"eighty":-1.720042,"marketCap":48756249},{"date":"2025-09-19","current":-0.611123,"twenty":-7.467367,"median":-3.24525,"eighty":-1.70231,"marketCap":52530927},{"date":"2025-09-26","current":-0.563551,"twenty":-7.467367,"median":-3.222807,"eighty":-1.693444,"marketCap":48441693},{"date":"2025-10-03","current":-0.680652,"twenty":-7.467367,"median":-3.207592,"eighty":-1.640246,"marketCap":58507499},{"date":"2025-10-10","current":-0.717246,"twenty":-7.461393,"median":-3.192079,"eighty":-1.613648,"marketCap":61653064},{"date":"2025-10-17","current":-0.684312,"twenty":-7.461393,"median":-3.15099,"eighty":-1.551584,"marketCap":58822056},{"date":"2025-10-24","current":-0.731884,"twenty":-7.449445,"median":-3.142012,"eighty":-0.871783,"marketCap":62911290},{"date":"2025-10-31","current":-0.709928,"twenty":-7.449445,"median":-3.137524,"eighty":-0.778377,"marketCap":61023951},{"date":"2025-11-07","current":-0.731884,"twenty":-7.431524,"median":-3.124058,"eighty":-0.764819,"marketCap":62911290},{"date":"2025-11-14","current":-0.7575,"twenty":-7.419576,"median":-3.074648,"eighty":-0.7575,"marketCap":65113185},{"date":"2025-11-21","current":-0.872339,"twenty":-7.413602,"median":-3.028172,"eighty":-0.7575,"marketCap":71314584},{"date":"2025-11-28","current":-0.910938,"twenty":-7.394485,"median":-3.011416,"eighty":-0.7575,"marketCap":74470097},{"date":"2025-12-05","current":-0.930238,"twenty":-7.389706,"median":-2.985956,"eighty":-0.763355,"marketCap":76047853},{"date":"2025-12-12","current":-1.007436,"twenty":-7.384928,"median":-2.942357,"eighty":-0.772552,"marketCap":82358878},{"date":"2025-12-19","current":-0.872339,"twenty":-7.374175,"median":-2.916361,"eighty":-0.777599,"marketCap":71314584},{"date":"2025-12-26","current":-0.922518,"twenty":-7.361032,"median":-2.855687,"eighty":-0.783416,"marketCap":75416751},{"date":"2026-01-02","current":-0.930238,"twenty":-7.351473,"median":-2.838136,"eighty":-0.788086,"marketCap":76047853},{"date":"2026-01-09","current":-0.744962,"twenty":-7.34311,"median":-2.832314,"eighty":-0.788086,"marketCap":60901393},{"date":"2026-01-16","current":-0.721803,"twenty":-7.335941,"median":-2.819283,"eighty":-0.760428,"marketCap":59008085},{"date":"2026-01-23","current":-0.783561,"twenty":-7.334746,"median":-2.806151,"eighty":-0.758852,"marketCap":64056905},{"date":"2026-01-30","current":-0.725663,"twenty":-7.326384,"median":-2.795895,"eighty":-0.7575,"marketCap":59323636},{"date":"2026-02-06","current":-0.617585,"twenty":-7.309656,"median":-2.788419,"eighty":-0.745274,"marketCap":50488201},{"date":"2026-02-13","current":-0.609865,"twenty":-7.298903,"median":-2.772248,"eighty":-0.73408,"marketCap":49857099},{"date":"2026-02-20","current":-0.609865,"twenty":-7.294124,"median":-2.745282,"eighty":-0.728225,"marketCap":49857099},{"date":"2026-02-27","current":-0.710223,"twenty":-7.274688,"median":-2.729735,"eighty":-0.721803,"marketCap":58061431},{"date":"2026-03-06","current":-0.617585,"twenty":-7.272415,"median":-2.715921,"eighty":-0.709928,"marketCap":50488201},{"date":"2026-03-13","current":-0.621445,"twenty":-7.252307,"median":-2.706027,"eighty":-0.698949,"marketCap":50803752},{"date":"2026-03-20","current":-0.688579,"twenty":-7.222437,"median":-2.690082,"eighty":-0.69163,"marketCap":53643714},{"date":"2026-03-27","current":-0.706208,"twenty":-7.174646,"median":-2.677713,"eighty":-0.69163,"marketCap":55017113},{"date":"2026-04-02","current":-0.726101,"twenty":-7.160309,"median":-2.650898,"eighty":-0.691215,"marketCap":56566891},{"date":"2026-04-10","current":-0.770861,"twenty":-7.142387,"median":-2.631196,"eighty":-0.691562,"marketCap":60053891},{"date":"2026-04-17","current":-0.83054,"twenty":-7.124465,"median":-2.604905,"eighty":-0.69163,"marketCap":64703224},{"date":"2026-04-24","current":-0.939953,"twenty":-7.092207,"median":-2.581276,"eighty":-0.69724,"marketCap":73227002},{"date":"2026-05-01","current":-0.920059,"twenty":-7.056364,"median":-2.557279,"eighty":-0.698888,"marketCap":71677225},{"date":"2026-05-08","current":-1.009579,"twenty":-7.039637,"median":-2.531504,"eighty":-0.698949,"marketCap":78651225},{"date":"2026-05-15","current":-1.063567,"twenty":-7.032468,"median":-2.507803,"eighty":-0.698949,"marketCap":82178597},{"date":"2026-05-22","current":-0.991554,"twenty":-7.021715,"median":-2.504465,"eighty":-0.701877,"marketCap":76614421},{"date":"2026-05-29","current":-0.902924,"twenty":-6.99816,"median":-2.503431,"eighty":-0.703702,"marketCap":69766205},{"date":"2026-06-05","current":-0.858608,"twenty":-6.971164,"median":-2.496557,"eighty":-0.705497,"marketCap":66342097},{"date":"2026-06-12","current":-0.797675,"twenty":-6.957196,"median":-2.457807,"eighty":-0.706301,"marketCap":61633948},{"date":"2026-06-18","current":-0.84199,"twenty":-6.944054,"median":-2.43502,"eighty":-0.707789,"marketCap":65058056},{"date":"2026-06-26","current":-0.875234,"twenty":-6.891484,"median":-2.424905,"eighty":-0.710046,"marketCap":67626731},{"date":"2026-07-02","current":-0.958326,"twenty":-6.812071,"median":-2.390526,"eighty":-0.711628,"marketCap":74046991},{"date":"2026-07-10","current":-1.135589,"twenty":-6.715379,"median":-2.382756,"eighty":-0.717797,"marketCap":87743544},{"date":"2026-07-17","current":-0.969405,"twenty":-6.663332,"median":-2.341987,"eighty":-0.72036,"marketCap":74903025},{"date":"2026-07-24","current":-0.925089,"twenty":-6.547986,"median":-2.330443,"eighty":-0.722355,"marketCap":71478887},{"date":"2026-07-31","current":-0.841998,"twenty":-6.379188,"median":-2.303374,"eighty":-0.724565,"marketCap":65058628},{"date":"2026-08-07","current":-0.936168,"twenty":-6.217422,"median":-2.300778,"eighty":-0.725663,"marketCap":72334922},{"date":"2026-08-14","current":-1.0668,"twenty":-6.182256,"median":-2.273702,"eighty":-0.726101,"marketCap":79183198},{"date":"2026-08-21","current":-1.270157,"twenty":-6.10495,"median":-2.265134,"eighty":-0.728225,"marketCap":94277396}],"updateTime":1787587973380},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ACRV\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659183214","title":"Acrivon Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659183214","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659183214?lang=en_us&edition=fundamental","pubTime":"2026-08-13 05:24","pubTimestamp":1786569882,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryAcrivon Therapeutics, Inc.ACRV.OQreported a quarterly adjusted loss of 43 cents per share for the quarter end","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N44928H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907297","title":"Acrivon Therapeutics, Inc Q2 Income from Operations USD -18.668 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907297?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:06","pubTimestamp":1786565164,"startTime":"0","endTime":"0","summary":"BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 MillionAug 12 (Reuters) - Acrivon Therapeutics, Inc Q2 basic EPS USD -0.43.Q2 net income USD -17.964 millionQ2 operating expenses USD 18.668 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXPKRR9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659071529","title":"Acrivon Therapeutics, Inc Q2 Basic EPS USD -0.43","url":"https://stock-news.laohu8.com/highlight/detail?id=2659071529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659071529?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nPLXPKRR9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907724","title":"Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907724","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907724?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"Arm 3 with ultra-low dose gemcitabine sensitization) in the. registrational-intent Phase 2b study, across both US and European. -- Two presentations at the American Association for Cancer Research . Annual Meeting highlighted data showing the underlying molecular. mechanisms for potent synergies between ACR-368 and immune checkpoint. AP3. These findings support the potential for clinical combination. studies with antibody-drug conjugates  or ICIs.ACR-2316-- ACR-2316 advanced into the randomized dose expansion stage of the Phase. 1/2 study, supported by observed favorable safety profile and durable. antitumor activity. The expansion phase is evaluating 120 mg and 160 mg. doses, administered orally, once-daily  utilizing a 3d on / 4d off. -- Dose expansion phase will assess safety and activity in subjects with","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4201","BK4139","EC","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657723621","title":"Acrivon Therapeutics, Inc. Expected to Post a Loss of 50 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657723621","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657723621?lang=en_us&edition=fundamental","pubTime":"2026-08-08 07:06","pubTimestamp":1786143968,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics, Inc. <ACRV.OQ> expected to post a loss of50cents a share - Earnings PreviewAcrivon Therapeutics, Inc.ACRV.OQACRV.Ois expected to  show no change in quarterly revenue when it repo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542815","title":"Acrivon Advances ACR-2316 into Randomized Dose Expansion in Phase 1/2 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542815","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542815?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:31","pubTimestamp":1785933119,"startTime":"0","endTime":"0","summary":"Acrivon advances ACR-2316 into randomized dose expansion in Phase 1/2 trialAcrivon Therapeutics advanced ACR-2316 into randomized dose expansion in its ongoing Phase 1/2 trial, based on dose-escalatio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLy5qY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","ACRV","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","BCDF","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544029","title":"Acrivon Advances Acr-2316, a Potential First-in-Class Wee1/Pkmyt1 Inhibitor, into Randomized Dose Expansion in Its Ongoing Phase 1/2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544029?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:30","pubTimestamp":1785933002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA3FGQZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653836147","title":"Acrivon Therapeutics Announces Availability of New Press Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2653836147","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653836147?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:31","pubTimestamp":1784665911,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics announces availability of new press releaseAcrivon posted a press release outlining AACR D3 2026 oral and poster presentations highlighting its AP3 platform, centered on WEE1/PKMY","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL2PFTvH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","ACRV","BK4139","IE00BN0W2T93.GBP","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650615960","title":"Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650615960","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650615960?lang=en_us&edition=fundamental","pubTime":"2026-07-11 21:15","pubTimestamp":1783775713,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/will-acrivon-therapeutics-nasdaqacrv-spend-its-cash-wisely-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/will-acrivon-therapeutics-nasdaqacrv-spend-its-cash-wisely-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NDX","ACRV","MNQmain","BK4139","IYW","JEPQ","GPIQ","TQQY","QQQJ","QQQ","QQQM","QID","QDTE","SQQQ","QYLG","TECS","QQQY","TQQQ","QQQE",".IXIC","NVIW.SI","NQmain","PSQ","QLD","QQQA","FTEC","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644072401","title":"Acrivon Therapeutics shareholders approve amended 2022 equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2644072401","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644072401?lang=en_us&edition=fundamental","pubTime":"2026-06-18 05:28","pubTimestamp":1781731722,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics held its annual shareholder meeting on June 17, 2026.Shareholders adopted an amended and restated 2022 Equity Incentive Plan, lifting the share pool to 8,606,723 shares.The plan also provides for automatic annual share reserve increases through 2032 equal to 5% of fully diluted shares, unless the board sets less.Two directors were chosen to serve as Class I directors through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6Mrj1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637179338","title":"Acrivon CEO joins TD Cowen Oncology Innovation Summit virtual fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637179338","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637179338?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:31","pubTimestamp":1779363078,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics will take part in a virtual fireside chat at TD Cowen’s 7th Annual Oncology Innovation Summit on May 26, 2026, at 9:00 a.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL6JnhFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4585","ACRV","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856326","title":"Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856326","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856326?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:43","pubTimestamp":1779191015,"startTime":"0","endTime":"0","summary":"Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/pleasing-signs-as-a-number-of-insiders-buy-acrivon-therapeut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acrv/acrivon-therapeutics/news/pleasing-signs-as-a-number-of-insiders-buy-acrivon-therapeut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","LENZ","BK4007","ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037358","title":"Acrivon grants employee stock options for 111,150 shares under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037358","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037358?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:00","pubTimestamp":1778875218,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics granted stock options covering 111,150 common shares to one new employee under its 2023 Inducement Plan, with a grant date of May 15, 2026.Exercise price set at Nasdaq closing price for Acrivon shares on grant date.Vesting set at 25% on first anniversary of first day of month following employment start date, with remaining options vesting in 2.083% monthly installments, contingent on continued employment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4Ln5TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0314104364.USD","ACRV","SG9999014039.USD","BK4139","SG9999014013.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037877","title":"Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037877?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:00","pubTimestamp":1778875200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA76KHGH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635743869","title":"Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635743869","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635743869?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:39","pubTimestamp":1778765963,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst reiterated a Buy rating on Acrivon Therapeutics, Inc. today and set a price target of $8.00. Acrivon Therapeutics, Inc. has an ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acrivon-therapeutics-inc-acrv-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acrivon-therapeutics-inc-acrv-receives-a-buy-from-oppenheimer-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4139","OPY","ACRV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635545937","title":"Acrivon Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635545937","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635545937?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:46","pubTimestamp":1778712378,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAcrivon Therapeutics Inc ACRV.OQ reported a quarterly adjusted loss of 49 cents per share for the quarter ende","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q311:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635779753","title":"Acrivon Therapeutics Q1 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2635779753","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635779753?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:25","pubTimestamp":1778703904,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics Q1 net loss narrowsOverviewU.S. oncology drug developer posted Q1 net loss of $19.0 mln, narrowing from prior yearOperating expenses for Q1 were materially consistent year over ye","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL1N41Q16W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753658","title":"Acrivon net loss narrows to $19 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753658?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:14","pubTimestamp":1778703295,"startTime":"0","endTime":"0","summary":"Acrivon Therapeutics posted a first-quarter net loss of USD 19 million, narrowing from a net loss of USD 19.7 million a year earlier.R&D expense held nearly flat at USD 15.2 million, while G&A expense fell to USD 4.7 million from USD 6.2 million.Cash, cash equivalents and marketable securities totaled USD 97.7 million as of March 31, 2026; subsequent equity financing added USD 7.3 million, extending expected runway into third quarter 2027.For ACR-368, Acrivon plans a prespecified simultaneous interim analysis and data update for both biopsy-independent serous endometrial cancer arms in second half 2026, with Phase 3 combination-trial readiness targeted by mid-2026.ACR-2316 Phase 1/2 data continued to show favorable tolerability mainly limited to transient neutropenia, with durable activity at weekly dosing regimens in AP3-prioritized tumors, including heavily pretreated lung cancers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4NNShv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635858753","title":"Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2635858753","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635858753?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:10","pubTimestamp":1778703002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nTUA17ZQ5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACRV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753830","title":"Acrivon Therapeutics, Inc Q1 Income From Operations USD -19.902 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753830","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753830?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:10","pubTimestamp":1778703000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nPLXC2FE50:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACRV"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}]}}